Investor Centre

Welcome to Rhythm Biosciences' (ASX:RHY) Investor Centre, your gateway to essential information about our innovative cancer detection and risk assessment technologies.

Here you'll find our latest announcements, financial reports, corporate governance information, and shareholder resources. Our journey represents a significant opportunity in the growing cancer diagnostics market, where early detection saves lives and reduces healthcare costs.

We appreciate your interest in Rhythm Biosciences and invite you to explore how we’re working to create long-term value for patients and shareholders alike. 

20260217 Rhythm Biosciences enters ColoSTAT® services agreement with 4Cyte Pathology
20260217 Rhythm Biosciences enters ColoSTAT® services agreement with 4Cyte Pathology
20260211 Rhythm Biosciences achieves commercial deployment milestone: First physician participant enrolled in the ColoSTAT® Access Program
20260211 Rhythm Biosciences achieves commercial deployment milestone: First physician participant enrolled in the ColoSTAT® Access Program
20260203 Rhythm Biosciences Secures Commercial Manufacturing Agreement for ColoSTAT®
20260203 Rhythm Biosciences Secures Commercial Manufacturing Agreement for ColoSTAT®
20260129 Rhythm Biosciences establishes strategic partnership with AGRF to accelerate commercial scale-up of the Genetype service
20260129 Rhythm Biosciences establishes strategic partnership with AGRF to accelerate commercial scale-up of the Genetype service
20260128 Rhythm Biosciences secures strategic US platform partnership with Cancer IQ to accelerate geneTypeTM commercial adoption
20260128 Rhythm Biosciences secures strategic US platform partnership with Cancer IQ to accelerate geneTypeTM commercial adoption
20260121 Landmark Publication Validates ColoSTAT® Clinical Performance
20260121 Landmark Publication Validates ColoSTAT® Clinical Performance
20260114 Enhanced Genetype colorectal cancer risk test released – supports earlier disease detection and ColoSTAT® targeting
20260114 Enhanced Genetype colorectal cancer risk test released – supports earlier disease detection and ColoSTAT® targeting
20251222 RHYTHM BIOSCIENCES LIMITED: 2025 - A Year in Review
20251222 RHYTHM BIOSCIENCES LIMITED: 2025 - A Year in Review
20251212 Rhythm Initiates Commercialisation of ColoSTAT® Following Updated Laboratory ISO15189:2022 Accreditation
20251212 Rhythm Initiates Commercialisation of ColoSTAT® Following Updated Laboratory ISO15189:2022 Accreditation
20251210 National Health Service of England Evaluation of ColoSTAT®
20251210 National Health Service of England Evaluation of ColoSTAT®
20251209 RHY enters a US marketing partnership with catch Bio
20251209 RHY enters a US marketing partnership with catch Bio
NATA ISO15189 Certification Genetype Laboratory Operations
NATA ISO15189 Certification Genetype Laboratory Operations
20251201 Genetype Ovarian Cancer Publication vFinal
20251201 Genetype Ovarian Cancer Publication vFinal
FY2025 R&D Tax Incentive Received & EndPoints Capital Loan Repayment
FY2025 R&D Tax Incentive Received & EndPoints Capital Loan Repayment
20251105 RHY Results of Annual General Meeting
20251105 RHY Results of Annual General Meeting
20251105 Rhythm Biosciences appoints new Chair
20251105 Rhythm Biosciences appoints new Chair
20251105 RHY Post-AGM Presentation
20251105 RHY Post-AGM Presentation
20251105 RHY Appendix 3Z Final Director’s Interest Notice
20251105 RHY Appendix 3Z Final Director’s Interest Notice
RHY Appendix 4G - Corporate Governance Council Principles and Recommendations
RHY Appendix 4G - Corporate Governance Council Principles and Recommendations
RHY-Appendix-4E-30-June-2025
RHY-Appendix-4E-30-June-2025
Rhythm Financial Report 30 June 2025
Rhythm Financial Report 30 June 2025
20250828 Genetype-KYLs Co-Marketing Agreement
20250828 Genetype-KYLs Co-Marketing Agreement
20250826-ColoSTAT Kit Validation Completion and NATA Submission vF
20250826-ColoSTAT Kit Validation Completion and NATA Submission vF
20250818 RHY - Target Market Determination - 2025 Options Prospectus
20250818 RHY - Target Market Determination - 2025 Options Prospectus
20250818 Prospectus for the issue of options
20250818 Prospectus for the issue of options
20250818 Share Placement to Raise Up To $3.75 million
20250818 Share Placement to Raise Up To $3.75 million
20250818 Appendix 3B - Proposed issue of securities
20250818 Appendix 3B - Proposed issue of securities
20250818 Appendix 3B - Proposed issue of securities
20250818 Appendix 3B - Proposed issue of securities
20250818 Placement Issue Investor Presentation
20250818 Placement Issue Investor Presentation
20250804 ColoSTAT Clinical Performance Data
20250804 ColoSTAT Clinical Performance Data
20250731 Quarterly Activities Report and Appendix 4C 31 July 2025
20250731 Quarterly Activities Report and Appendix 4C 31 July 2025
20250724 MSK Collaboration
20250724 MSK Collaboration
20250717- geneType™ Australian Pathology Pilot
20250717- geneType™ Australian Pathology Pilot
25-05-02 Notification regarding unquoted securities - RHY
25-05-02 Notification regarding unquoted securities - RHY
25-05-01 Proposed issue of securities - RHY
25-05-01 Proposed issue of securities - RHY
25-04-24 Quarterly Activities Report and Appendix 4C 31 March 2025
25-04-24 Quarterly Activities Report and Appendix 4C 31 March 2025
25-04-14 RHY ISO13485 Recert Market Update
25-04-14 RHY ISO13485 Recert Market Update
25-04-11 Application for quotation of securities - RHY
25-04-11 Application for quotation of securities - RHY
25-04-08 Change in substantial holding
25-04-08 Change in substantial holding
25-03-31 EGM - Investor Presentation
25-03-31 EGM - Investor Presentation
25-03-31 RHY - Results of Meeting
25-03-31 RHY - Results of Meeting
25-03-19 RHY geneType™ Commercial Sales
25-03-19 RHY geneType™ Commercial Sales
25-03-18 Appointment of Chief Financial Officer
25-03-18 Appointment of Chief Financial Officer
25-03-18 Notification regarding unquoted securities - RHY
25-03-18 Notification regarding unquoted securities - RHY
25-03-17 Notification of cessation of securities - RHY
25-03-17 Notification of cessation of securities - RHY
25-03-05 RHY Investor Webinar
25-03-05 RHY Investor Webinar
25-02-27 RHY - EGM Notice of Meeting and Proxy Form
25-02-27 RHY - EGM Notice of Meeting and Proxy Form
25-02-27 Investor Webinar
25-02-27 Investor Webinar
25-02-21 Half-Year Financial Report and Appendix 4D
25-02-21 Half-Year Financial Report and Appendix 4D
25-02-12 Becoming a substantial holder
25-02-12 Becoming a substantial holder
25-02-04 geneType™ Commercial Integration Completion
25-02-04 geneType™ Commercial Integration Completion
25-01-23 Quarterly Activities Report and Appendix 4C - Dec24
25-01-23 Quarterly Activities Report and Appendix 4C - Dec24
25-01-14 About the geneType™ Acquisition
25-01-14 About the geneType™ Acquisition
Imported file is not an image
2024 Announcements
24-12-24 - Completion of geneType™ Risk Assessment Portfolio Acquisition
24-12-24 - Completion of geneType™ Risk Assessment Portfolio Acquisition
23-Dec-24 - RHY geneType™ acquisition
23-Dec-24 - RHY geneType™ acquisition
20-Dec-24 Request for Trading Halt
20-Dec-24 Request for Trading Halt
18-Dec-2024 - Market Update - All End of CY24 Milestones Attained
18-Dec-2024 - Market Update - All End of CY24 Milestones Attained
2-Dec-2024 - Change in substantial holding - Otto Buttula
2-Dec-2024 - Change in substantial holding - Otto Buttula
2-Dec-2024 - Initial Director's Interest Notice
2-Dec-2024 - Initial Director's Interest Notice
2-Dec-2024 - Board Changes Effected
2-Dec-2024 - Board Changes Effected
29-Nov-2024 - Application for quotation of securities - RHY
29-Nov-2024 - Application for quotation of securities - RHY
21-Nov-2024 - Final Director's Interest Notice - Lou Panaccio
21-Nov-2024 - Final Director's Interest Notice - Lou Panaccio
21-Nov-2024 - Final Director's Interest Notice - Trevor Lockett
21-Nov-2024 - Final Director's Interest Notice - Trevor Lockett
20-Nov-2024 - 2024 AGM Results
20-Nov-2024 - 2024 AGM Results
20-Nov-2024 - 2024 AGM Chairman's Address & Post AGM Presentation
20-Nov-2024 - 2024 AGM Chairman's Address & Post AGM Presentation
20-Nov-2024 - Board Composition Update - NED Resignations
20-Nov-2024 - Board Composition Update - NED Resignations
19-Nov-2024 - Proposed issue of securities
19-Nov-2024 - Proposed issue of securities
19-Nov-2024 - Placement Issue Investor Presentation
19-Nov-2024 - Placement Issue Investor Presentation
19-Nov-2024 - Placement Prospectus
19-Nov-2024 - Placement Prospectus
19-Nov-2024 - Strong Demand in Share Placement to Raise $3.5 million
19-Nov-2024 - Strong Demand in Share Placement to Raise $3.5 million
18-Nov-2024 - Notification regarding unquoted securities RHY
18-Nov-2024 - Notification regarding unquoted securities RHY
18-Nov-2024 - Notification regarding unquoted securities
18-Nov-2024 - Notification regarding unquoted securities
18-Nov-2024 - Awarding of Employee Options and Loan Shares to Management
18-Nov-2024 - Awarding of Employee Options and Loan Shares to Management
15-Nov-2024 - Trading Halt
15-Nov-2024 - Trading Halt
11-Nov-2024 - New, Independent, Non-Executive Director to be Appointed
11-Nov-2024 - New, Independent, Non-Executive Director to be Appointed
7-Nov-2024 - Receipt of Research & Development Tax Incentive
7-Nov-2024 - Receipt of Research & Development Tax Incentive
24-Oct-2024 - Market Presentation
24-Oct-2024 - Market Presentation
24-Oct-2024 - Appendix 4C and Market Update
24-Oct-2024 - Appendix 4C and Market Update
18-Oct-2024 - RHY 2024 AGM Nominations & Proxy Form
18-Oct-2024 - RHY 2024 AGM Nominations & Proxy Form
7-Oct-2024 - 2nd Generation, ColoSTAT Multiplex Alpha Kit Outperforms
7-Oct-2024 - 2nd Generation, ColoSTAT Multiplex Alpha Kit Outperforms
30-Sep-2024 - Initial Director's Interest Notice - David Atkins
30-Sep-2024 - Initial Director's Interest Notice - David Atkins
30-Sep-2024 - Board Renewal - Composition Update
30-Sep-2024 - Board Renewal - Composition Update
26-Sep-2024 - Corporate Governance Statement
26-Sep-2024 - Corporate Governance Statement
26-Sep-2024 - RHY FY2024 Annual Report
26-Sep-2024 - RHY FY2024 Annual Report
24-Sep-2024 - Platform Expansion - Gastric Cancer Diagnostic Test Update
24-Sep-2024 - Platform Expansion - Gastric Cancer Diagnostic Test Update
10-Sep-2024 -AGM date and closing date for director nominations
10-Sep-2024 -AGM date and closing date for director nominations
30-Aug-2024 - Appendix 4G
30-Aug-2024 - Appendix 4G
30-Aug-2024 - RHY Financial Report FY2024
30-Aug-2024 - RHY Financial Report FY2024
30-Aug-2024 - Appendix 4E
30-Aug-2024 - Appendix 4E
28-Aug-2024 - Product and Market Update - Phase 2 Milestone
28-Aug-2024 - Product and Market Update - Phase 2 Milestone
19-Aug-2024 - Notification of cessation of securities
19-Aug-2024 - Notification of cessation of securities
14-Aug-2024 - FY2024 R&D Tax Incentive Loan Funding
14-Aug-2024 - FY2024 R&D Tax Incentive Loan Funding
7-Aug-2024 - Change of Director's Interest Notice - Otto Buttula
7-Aug-2024 - Change of Director's Interest Notice - Otto Buttula
7-Aug-2024 - Change of Director's Interest Notice - Lou Panaccio
7-Aug-2024 - Change of Director's Interest Notice - Lou Panaccio
7-Aug-2024 - Change of Director's Interest Notice - Trevor Lockett
7-Aug-2024 - Change of Director's Interest Notice - Trevor Lockett
1-Aug-2024 - Notification of cessation of securities
1-Aug-2024 - Notification of cessation of securities
29-July-2024 - Quarterly Activities Report and Appendix 4C
29-July-2024 - Quarterly Activities Report and Appendix 4C
12-July-2024 - Bioshares Biotech Summit Presentation
12-July-2024 - Bioshares Biotech Summit Presentation
17-June-2024 - Close of Shortfall Offer Pursuant to the Rights Issue
17-June-2024 - Close of Shortfall Offer Pursuant to the Rights Issue
17-June-2024 - Change of Director's Interest Notice - Otto Buttula
17-June-2024 - Change of Director's Interest Notice - Otto Buttula
04-June-2024 - Change of Director's Interest Notice - Otto Buttula
04-June-2024 - Change of Director's Interest Notice - Otto Buttula
28-May-2024 - Change of Director's Interest Notice - Otto Buttula
28-May-2024 - Change of Director's Interest Notice - Otto Buttula
27-May-2024 - Cancel - Notification regarding unquoted securities
27-May-2024 - Cancel - Notification regarding unquoted securities
27-May-2024 - Notification regarding unquoted securities
27-May-2024 - Notification regarding unquoted securities
27-May-2024 - Notification regarding unquoted securities
27-May-2024 - Notification regarding unquoted securities
27-May-2024 - Notification regarding unquoted securities
27-May-2024 - Notification regarding unquoted securities
22-May-2024 - Otto Buttula to Revert Back to Non-Executive Chair
22-May-2024 - Otto Buttula to Revert Back to Non-Executive Chair
7-May-2024 - Application for quotation of securities
7-May-2024 - Application for quotation of securities
30-April-2024 - Quarterly Activities Report and Appendix 4C
30-April-2024 - Quarterly Activities Report and Appendix 4C
24-April-2024 - Dr David Atkins Appointed Chief Executive Officer of Rhythm Biosciences
24-April-2024 - Dr David Atkins Appointed Chief Executive Officer of Rhythm Biosciences
23-April-2024 - Rhythm Maintains ISO Certification
23-April-2024 - Rhythm Maintains ISO Certification
2-April-2024 - Change in substantial holding - Otto Buttula
2-April-2024 - Change in substantial holding - Otto Buttula
27-March-2024 - Change of Director's Interest Notice - Trevor Lockett
27-March-2024 - Change of Director's Interest Notice - Trevor Lockett
27-March-2024 - Change of Director's Interest Notice - Lou Panaccio
27-March-2024 - Change of Director's Interest Notice - Lou Panaccio
27-March-2024 - Change of Director's Interest Notice - Otto Buttula
27-March-2024 - Change of Director's Interest Notice - Otto Buttula
25-March-2024 - Notice of ceasing to be a substantial holder
25-March-2024 - Notice of ceasing to be a substantial holder
21-March-2024 - Distribution schedule - RHYO options
21-March-2024 - Distribution schedule - RHYO options
21-March-2024 - Top 20 securityholders - RHYO options
21-March-2024 - Top 20 securityholders - RHYO options
21-March-2024 - Update - Application for quotation of securities
21-March-2024 - Update - Application for quotation of securities
21-March-2024 - Close of Rights Issue
21-March-2024 - Close of Rights Issue
21-March-2024 - Application for quotation of securities
21-March-2024 - Application for quotation of securities
19-March-2024 - Internationally Renowned Clinical Advisory Board Established
19-March-2024 - Internationally Renowned Clinical Advisory Board Established
1-Mar-2024 - S&P DJI Announces March 2024 Quarterly Rebalance
1-Mar-2024 - S&P DJI Announces March 2024 Quarterly Rebalance
29-Feb-2024 - Half Yearly Report and Accounts
29-Feb-2024 - Half Yearly Report and Accounts
28-Feb-2024 - Non-Renounceable Issue - Ineligible Holder Letter
28-Feb-2024 - Non-Renounceable Issue - Ineligible Holder Letter
27-Feb-2024 - Dispatch of Rights Issue Offer Prospectus
27-Feb-2024 - Dispatch of Rights Issue Offer Prospectus
21-Feb-2024 - Rights Issue Investor Presentation
21-Feb-2024 - Rights Issue Investor Presentation
20-Feb-2024 - PAC Partners Appointed Lead Manager
20-Feb-2024 - PAC Partners Appointed Lead Manager
19-Feb-2024 - Rights Issue - Optionholder Letter
19-Feb-2024 - Rights Issue - Optionholder Letter
19-Feb-2024 - Prospectus - 2024 Non-Renounceable Rights Issue
19-Feb-2024 - Prospectus - 2024 Non-Renounceable Rights Issue
16-Feb-2024 - Appendix 3H - Notification of cessation of securities
16-Feb-2024 - Appendix 3H - Notification of cessation of securities
16-Feb-2024 - Market Update
16-Feb-2024 - Market Update
12-Feb-2024 - Results of Extraordinary General Meeting
12-Feb-2024 - Results of Extraordinary General Meeting
12-Feb-2024 - EGM Slides
12-Feb-2024 - EGM Slides
9-Feb-2024 - Proposed issue of securities - RHY
9-Feb-2024 - Proposed issue of securities - RHY
9-Feb-2024 - Rights Issue Offer to Raise Up To $6.6 million
9-Feb-2024 - Rights Issue Offer to Raise Up To $6.6 million
8-Feb-2024 - Update re EGM 12 February 2024
8-Feb-2024 - Update re EGM 12 February 2024
7-Feb-2024 - Trading Halt
7-Feb-2024 - Trading Halt
31-Jan-2024 - Quarterly Activities Report and Appendix 4C
31-Jan-2024 - Quarterly Activities Report and Appendix 4C
04-Jan-2024 - EGM Notice of Meeting
04-Jan-2024 - EGM Notice of Meeting
2023 Announcements
29-Dec-2023 - Appendix 3Z - Final Directors Interest Notice
29-Dec-2023 - Appendix 3Z - Final Directors Interest Notice
29-Dec-2023 - Resignation of Dr Rachel David as Non-executive Director
29-Dec-2023 - Resignation of Dr Rachel David as Non-executive Director
18-Dec-2023 - Strategy and Market Update
18-Dec-2023 - Strategy and Market Update
15-Dec-2023 - Receipt of Notice under Section 249D of the Corporations Act
15-Dec-2023 - Receipt of Notice under Section 249D of the Corporations Act
14-Dec-2023 - Notice of Initial Substantial Holder
14-Dec-2023 - Notice of Initial Substantial Holder
14-Dec-2023 - Appointment of Joint Company Secretary
14-Dec-2023 - Appointment of Joint Company Secretary
24-Nov-2023 - Platform Expansion - Lung Cancer Diagnostic Test Update
24-Nov-2023 - Platform Expansion - Lung Cancer Diagnostic Test Update
15-Nov-2023 - Executive Management Changes
15-Nov-2023 - Executive Management Changes
14-Nov-2023 - Receipt of First Tranche of $1.69m in R&D Tax Incentive
14-Nov-2023 - Receipt of First Tranche of $1.69m in R&D Tax Incentive
31-Oct-2023 - Appendix 4C and Market Update
31-Oct-2023 - Appendix 4C and Market Update
24-Oct-2023 - Appendix 3Y - Change of Directors Interest Notice
24-Oct-2023 - Appendix 3Y - Change of Directors Interest Notice
24-Oct-2023 - Notification regarding unquoted securities
24-Oct-2023 - Notification regarding unquoted securities
18-October-2023 - Response to ASX Query
18-October-2023 - Response to ASX Query
13-October-2023 - Response to ASX Price Query
13-October-2023 - Response to ASX Price Query
13-October-2023 - Pause in Trading
13-October-2023 - Pause in Trading
12-October-2023 - Notice of Initial Substantial Holder
12-October-2023 - Notice of Initial Substantial Holder
10-October-2023 - RHY 2023 AGM Results
10-October-2023 - RHY 2023 AGM Results
10-October-2023 - RHY 2023 AGM Presentation
10-October-2023 - RHY 2023 AGM Presentation
21-September-2023 Breast Cancer Diagnostic Test Update
21-September-2023 Breast Cancer Diagnostic Test Update
18-September-2023 Notification of cessation of +securities
18-September-2023 Notification of cessation of +securities
13-September-2023 RHY Contracts with Nutripath on Automation
13-September-2023 RHY Contracts with Nutripath on Automation
12-September-2023 Application for quotation of +securities
12-September-2023 Application for quotation of +securities
12-September-2023 Cleansing Notice
12-September-2023 Cleansing Notice
01-Sep-2023 AGM Nominations & Proxy Form
01-Sep-2023 AGM Nominations & Proxy Form
Annual Financial Report - 2023
Annual Financial Report - 2023
31-August-2023 Appendix 4G and Corporate Governance Statement
31-August-2023 Appendix 4G and Corporate Governance Statement
31-August-2023 Appendix 4E
31-August-2023 Appendix 4E
08-August-2023 Application for quotation of +securities
08-August-2023 Application for quotation of +securities
08-August-2023 Change of Directors Interest Notice
08-August-2023 Change of Directors Interest Notice
08-August-2023 Cleansing Notice
08-August-2023 Cleansing Notice
01-August-2023 Appendix 3Y - Change of Directors Interest Notice
01-August-2023 Appendix 3Y - Change of Directors Interest Notice
31-July-2023 Appendix 4C and Market Update
31-July-2023 Appendix 4C and Market Update
25-July-2023 Bioshares Summit Presentation
25-July-2023 Bioshares Summit Presentation
04-July-2023 Appointment of Independent, Deputy Chair
04-July-2023 Appointment of Independent, Deputy Chair
03-July-2023 Rhythm Establishes UK Subsidiary for Market Entry
03-July-2023 Rhythm Establishes UK Subsidiary for Market Entry
30-June-2023 Notification of cessation of +securities
30-June-2023 Notification of cessation of +securities
23-June-2023 Revised Securities Trading Policy
23-June-2023 Revised Securities Trading Policy
20-June-2023 Investor Presentation
20-June-2023 Investor Presentation
19-June-2023 Rhythm Continues Platform Expansion Program for Other Cancers
19-June-2023 Rhythm Continues Platform Expansion Program for Other Cancers
06-June-2023 ColoSTAT Poster Presentation at ASCO Annual Meeting
06-June-2023 ColoSTAT Poster Presentation at ASCO Annual Meeting
26-May-2023 Notification of cessation of +securities
26-May-2023 Notification of cessation of +securities
25-May-2023 Response to ASX Query
25-May-2023 Response to ASX Query
24-May-2023 UK Strategic Partnership with LINK Medical Solutions
24-May-2023 UK Strategic Partnership with LINK Medical Solutions
19-May-2023 Application for quotation of +securities
19-May-2023 Application for quotation of +securities
19-May-2023 Cleansing Notice
19-May-2023 Cleansing Notice
18-May-2023 Application for quotation of +securities
18-May-2023 Application for quotation of +securities
18-May-2023 Cleansing Notice
18-May-2023 Cleansing Notice
17-May-2023 UKCA Mark granted for ColoSTAT
17-May-2023 UKCA Mark granted for ColoSTAT
15-May-2023 Form 604 -Change of Interests of Substantial Holder
15-May-2023 Form 604 -Change of Interests of Substantial Holder
15-May-2023 Change of Director's Interest Notice
15-May-2023 Change of Director's Interest Notice
12-May-2023 Notification of cessation of +securities
12-May-2023 Notification of cessation of +securities
27-Apr-2023 Appendix 4C and Market Update
27-Apr-2023 Appendix 4C and Market Update
24-Apr-2023 Appendix 3Z - Final Directors Interest Notice
24-Apr-2023 Appendix 3Z - Final Directors Interest Notice
19-Apr-2023 Executive Management Change
19-Apr-2023 Executive Management Change
06-Apr-2023 ColoSTAT abstracts accepted at 2023 ASCO Annual Meeting
06-Apr-2023 ColoSTAT abstracts accepted at 2023 ASCO Annual Meeting
06-Mar-2023 Reinstatement to Official Quotation
06-Mar-2023 Reinstatement to Official Quotation
06-Mar-2023 Update to TGA Submission
06-Mar-2023 Update to TGA Submission
03-Mar-2023 Suspension from Official Quotation
03-Mar-2023 Suspension from Official Quotation
01-Mar-2023 Trading Halt
01-Mar-2023 Trading Halt
01-Mar-2023 Pause in Trading
01-Mar-2023 Pause in Trading
27-Feb-2023 Change of Share Registry Details
27-Feb-2023 Change of Share Registry Details
23-Feb-2023 Appendix 4D Interim Financial Report
23-Feb-2023 Appendix 4D Interim Financial Report
23-Feb-2023 RHY Institutional Presentation
23-Feb-2023 RHY Institutional Presentation
15-Feb-2023 Rhythm Maintains ISO Certification
15-Feb-2023 Rhythm Maintains ISO Certification
9-Feb-2023 Initial Director's Interest Notice
9-Feb-2023 Initial Director's Interest Notice
31-Jan-2023 Appendix 4C - Quarterly
31-Jan-2023 Appendix 4C - Quarterly
31-Jan-2023 Appointment of New Non-Executive Director
31-Jan-2023 Appointment of New Non-Executive Director
25-Jan-2023 Institutional Presentation
25-Jan-2023 Institutional Presentation
18-Jan-2023 Change of Director's Interest Notice x 2
18-Jan-2023 Change of Director's Interest Notice x 2
10-Jan-2023 Notification regarding unquoted securities - RHY
10-Jan-2023 Notification regarding unquoted securities - RHY
9-Jan-2023 Change of Directors Interest Notice x 4
9-Jan-2023 Change of Directors Interest Notice x 4
4-Jan-2023 Notification of cessation of securities - RHY
4-Jan-2023 Notification of cessation of securities - RHY
2022 Announcements
15-Dec-2022 Institutional Presentation
15-Dec-2022 Institutional Presentation
15-Dec-2022 Market Update
15-Dec-2022 Market Update
15-Dec-2022 RHY Continues Platform Expansion Program for Other Cancers
15-Dec-2022 RHY Continues Platform Expansion Program for Other Cancers
6-Dec-2022 MST Access Diagnostics Forum Presentation (Amended)
6-Dec-2022 MST Access Diagnostics Forum Presentation (Amended)
6-Dec-2022 MST Access Financial Diagnostics Presentation
6-Dec-2022 MST Access Financial Diagnostics Presentation
6-Dec-2022 Final Director's Interest Notice
6-Dec-2022 Final Director's Interest Notice
29-Nov-2022 RHY 2022 AGM Presentation
29-Nov-2022 RHY 2022 AGM Presentation
29-Nov-2022 Results of Meeting
29-Nov-2022 Results of Meeting
29-Nov-2022 Mr. Eduardo Vom Retires as a Non-executive Director
29-Nov-2022 Mr. Eduardo Vom Retires as a Non-executive Director
15-Nov-2022 Application for quotation of securities - RHY
15-Nov-2022 Application for quotation of securities - RHY
10-Nov-2022 Cleansing Notice
10-Nov-2022 Cleansing Notice
10-Nov-2022 Application for quotation of securities - RHY
10-Nov-2022 Application for quotation of securities - RHY
9-Nov-2022 Healthcare Conference Investor Presentation
9-Nov-2022 Healthcare Conference Investor Presentation
3-Nov-2022 ColoSTAT Authorised For Sale In New Zealand
3-Nov-2022 ColoSTAT Authorised For Sale In New Zealand
31-Oct-2022 Notice of Annual General Meeting-Proxy Form
31-Oct-2022 Notice of Annual General Meeting-Proxy Form
31-Oct-2022 Appendix 4C - Quarterly
31-Oct-2022 Appendix 4C - Quarterly
27-Oct-2022 Rhythm Expands Executive Management Team
27-Oct-2022 Rhythm Expands Executive Management Team
26-Oct-2022 Notification of cessation of securities - RHY
26-Oct-2022 Notification of cessation of securities - RHY
24-Oct-2022 Cleansing Notice
24-Oct-2022 Cleansing Notice
24-Oct-2022 Application for quotation of securities - RHY
24-Oct-2022 Application for quotation of securities - RHY
21-Oct-2022 Rhythm Receives $2.7m R&D Tax Incentive
21-Oct-2022 Rhythm Receives $2.7m R&D Tax Incentive
13-Oct-2022 Application for quotation of securities - RHY
13-Oct-2022 Application for quotation of securities - RHY
13-Oct-2022 Cleansing Notice
13-Oct-2022 Cleansing Notice
7-Oct-2022 Application for quotation of securities - RHY
7-Oct-2022 Application for quotation of securities - RHY
7-Oct-2022 Cleansing Notice
7-Oct-2022 Cleansing Notice
5-Oct-2022 Change of Director's Interest Notice x2
5-Oct-2022 Change of Director's Interest Notice x2
4-Oct-2022 Notification of cessation of securities - RHY
4-Oct-2022 Notification of cessation of securities - RHY
30-Sep-2022 Application for quotation of securities - RHY
30-Sep-2022 Application for quotation of securities - RHY
30-Sep-2022 Cleansing Notice
30-Sep-2022 Cleansing Notice
16-Sep-2022 Application for quotation of +securities
16-Sep-2022 Application for quotation of +securities
16-Sep-2022 Cleansing Notice
16-Sep-2022 Cleansing Notice
9-Sep-2022 Change in substantial holding - correction
9-Sep-2022 Change in substantial holding - correction
9-Sep-2022 Cleansing Notice
9-Sep-2022 Cleansing Notice
9-Sep-2022 Application for quotation of +securities
9-Sep-2022 Application for quotation of +securities
9-Sep-2022 Change in substantial holding
9-Sep-2022 Change in substantial holding
9-Sep-2022 Director Share Sale to Institutional Funds Manager
9-Sep-2022 Director Share Sale to Institutional Funds Manager
9-Sep-2022 Change of Director's Interest Notice
9-Sep-2022 Change of Director's Interest Notice
7-Sep-2022 Application for quotation of +securities
7-Sep-2022 Application for quotation of +securities
5-Sep-2022 Change of Director's Interest Notice - Corrected
5-Sep-2022 Change of Director's Interest Notice - Corrected
5-Sep-2022 Change of Director's Interest Notice
5-Sep-2022 Change of Director's Interest Notice
5-Sep-2022 Application for quotation of securities - RHY
5-Sep-2022 Application for quotation of securities - RHY
30-Aug-2022 Application for quotation of securities - RHY
30-Aug-2022 Application for quotation of securities - RHY
30-Aug-2022 Change of Director's Interest Notice
30-Aug-2022 Change of Director's Interest Notice
30-Aug-2022 Cleansing Statement
30-Aug-2022 Cleansing Statement
30-Aug-2022 Change of Director's Interest Notice
30-Aug-2022 Change of Director's Interest Notice
29-Aug-2022 Annual Report
29-Aug-2022 Annual Report
29-Aug-2022 Appendix 4E
29-Aug-2022 Appendix 4E
29-Aug-2022 Appendix 4G and Corporate Governance Statement
29-Aug-2022 Appendix 4G and Corporate Governance Statement
29-Aug-2022 Change of Director's Interest Notice
29-Aug-2022 Change of Director's Interest Notice
26-Aug-2022 Application for quotation of securities - RHY
26-Aug-2022 Application for quotation of securities - RHY
26-Aug-2022 Cleansing Notice
26-Aug-2022 Cleansing Notice
22-Aug-2022 Change of Director's Interest Notice
22-Aug-2022 Change of Director's Interest Notice
19-Aug-2022 Application for quotation of securities - RHY
19-Aug-2022 Application for quotation of securities - RHY
19-Aug-2022 Cleansing Statement
19-Aug-2022 Cleansing Statement
12-Aug-2022 Application for quotation of securities - RHY
12-Aug-2022 Application for quotation of securities - RHY
12-Aug-2022 Cleansing Notice
12-Aug-2022 Cleansing Notice
5-Aug-2022 Application for quotation of securities - RHY
5-Aug-2022 Application for quotation of securities - RHY
5-Aug-2022 Cleansing Notice
5-Aug-2022 Cleansing Notice
1-Aug-2022 Notification to option holders of expiry of unlisted options
1-Aug-2022 Notification to option holders of expiry of unlisted options
1-Aug-2022 Application for quotation of securities - RHY
1-Aug-2022 Application for quotation of securities - RHY
1-Aug-2022 Cleansing Notice
1-Aug-2022 Cleansing Notice
29-Jul-2022 Appendix 4C - Quarterly
29-Jul-2022 Appendix 4C - Quarterly
26-Jul-2022 Application for quotation of securities - RHY
26-Jul-2022 Application for quotation of securities - RHY
26-Jul-2022 Cleansing Notice
26-Jul-2022 Cleansing Notice
19-Jul-2022 RHY Advances Platform Expansion with Other Cancers
19-Jul-2022 RHY Advances Platform Expansion with Other Cancers
20-Jun-2022 Application for quotation of securities - RHY
20-Jun-2022 Application for quotation of securities - RHY
20-Jun-2022 Cleansing Notice
20-Jun-2022 Cleansing Notice
12-May-2022 Completion of Final TGA Submission Step to Approve ColoSTAT
12-May-2022 Completion of Final TGA Submission Step to Approve ColoSTAT
10-May-2022 Application for quotation of securities - RHY
10-May-2022 Application for quotation of securities - RHY
10-May-2022 Cleansing Notice
10-May-2022 Cleansing Notice
4-May-2022 Rhythm Closes Final Clinical Trial Site
4-May-2022 Rhythm Closes Final Clinical Trial Site
28-Apr-2022 Appendix 4C - quarterly
28-Apr-2022 Appendix 4C - quarterly
27-Apr-2022 Application for quotation of securities - RHY
27-Apr-2022 Application for quotation of securities - RHY
27-Apr-2022 Cleansing Notice
27-Apr-2022 Cleansing Notice
12-Apr-2022 Application for quotation of securities - RHY
12-Apr-2022 Application for quotation of securities - RHY
12-Apr-2022 Cleansing Notice
12-Apr-2022 Cleansing Notice
7-Apr-2022 Application for quotation of securities - RHY
7-Apr-2022 Application for quotation of securities - RHY
7-Apr-2022 Cleansing Notice
7-Apr-2022 Cleansing Notice
6-Apr-2022 RHY Presentation at PAC Partners Healthcare Conference
6-Apr-2022 RHY Presentation at PAC Partners Healthcare Conference
5-Apr-2022 Investor Presentation
5-Apr-2022 Investor Presentation
4-Apr-2022 Study 7 Confirms ColoSTAT Meets Primary Endpoint
4-Apr-2022 Study 7 Confirms ColoSTAT Meets Primary Endpoint
18-Mar-2022 Cleansing Notice
18-Mar-2022 Cleansing Notice
18-Mar-2022 Application for quotation of +securities
18-Mar-2022 Application for quotation of +securities
4-Mar-2022 S&P DJI Announces March 2022 Quarterly Rebalance
4-Mar-2022 S&P DJI Announces March 2022 Quarterly Rebalance
2-Mar-2022 Rhythm Biosciences - Investor Webinar Presentation
2-Mar-2022 Rhythm Biosciences - Investor Webinar Presentation
25-Feb-2022 Appendix 4D and Half Yearly Report and Accounts
25-Feb-2022 Appendix 4D and Half Yearly Report and Accounts
25-Feb-2022 Change of Company Address
25-Feb-2022 Change of Company Address
24-Feb-2022 Appointment of New Company Secretary and General Counsel
24-Feb-2022 Appointment of New Company Secretary and General Counsel
24-Feb-2022 Rhythm Investor Webinar
24-Feb-2022 Rhythm Investor Webinar
15-Feb-2022 Rhythm Maintains Ongoing ISO13485 Certification
15-Feb-2022 Rhythm Maintains Ongoing ISO13485 Certification
4-Feb-2022 Application for quotation of securities - RHY
4-Feb-2022 Application for quotation of securities - RHY
4-Feb-2022 Cleansing Notice
4-Feb-2022 Cleansing Notice
1-Feb-2022 Application for quotation of securities - RHY
1-Feb-2022 Application for quotation of securities - RHY
1-Feb-2022 Cleansing Notice
1-Feb-2022 Cleansing Notice
27-Jan-2022 Appendix 4C - quarterly
27-Jan-2022 Appendix 4C - quarterly
13-Jan-2022 Application for quotation of securities - RHY
13-Jan-2022 Application for quotation of securities - RHY
13-Jan-2022 Cleansing Notice
13-Jan-2022 Cleansing Notice
12-Jan-2022 Application for quotation of securities - RHY
12-Jan-2022 Application for quotation of securities - RHY
12-Jan-2022 Cleansing Notice
12-Jan-2022 Cleansing Notice
6-Jan-2022 Placement of $6.5m to Global Institutional Funds Manager
6-Jan-2022 Placement of $6.5m to Global Institutional Funds Manager
6-Jan-2022 Proposed issue of securities - RHY
6-Jan-2022 Proposed issue of securities - RHY
6-Jan-2022 Rhythm Expands CE Mark Registration for ColoSTAT
6-Jan-2022 Rhythm Expands CE Mark Registration for ColoSTAT
2021 Announcements
17-Dec-2021 Cleansing Notice
17-Dec-2021 Cleansing Notice
2021-12-17 Application for quotation of securities RHY
2021-12-17 Application for quotation of securities RHY
2021-12-15 Initial Directors Interest Notice
2021-12-15 Initial Directors Interest Notice
2021-12-14 RHY Platform Technology Targets Five Cancers
2021-12-14 RHY Platform Technology Targets Five Cancers
2021-12-13 Cleansing Notice
2021-12-13 Cleansing Notice
2021-12-13 Application for quotation of securities RHY
2021-12-13 Application for quotation of securities RHY
13-Dec-2021 Appointment of New Non-Executive Director
13-Dec-2021 Appointment of New Non-Executive Director
2-Dec-2021 Cleansing Notice
2-Dec-2021 Cleansing Notice
2-Dec-2021 Application for quotation of securities - RHY
2-Dec-2021 Application for quotation of securities - RHY
1-Dec-2021 Initial Director's Interest Notice
1-Dec-2021 Initial Director's Interest Notice
1-Dec-2021 Board and Management Restructure
1-Dec-2021 Board and Management Restructure
30-Nov-2021 CE Mark Granted for ColoSTAT
30-Nov-2021 CE Mark Granted for ColoSTAT
25-Nov-2021 Change of Director's Interest Notice x 4
25-Nov-2021 Change of Director's Interest Notice x 4
25-Nov-2021 Notification regarding unquoted securities - RHY
25-Nov-2021 Notification regarding unquoted securities - RHY
24-Nov-2021 Results of AGM
24-Nov-2021 Results of AGM
24-Nov-2021 Results of Meeting
24-Nov-2021 Results of Meeting
24-Nov-2021 AGM Presentation
24-Nov-2021 AGM Presentation
12-Nov-2021 Cleansing Notice
12-Nov-2021 Cleansing Notice
12-Nov-2021 Application for quotation of securities - RHY
12-Nov-2021 Application for quotation of securities - RHY
10-Nov-2021 RHY - Institutional Investor Presentation
10-Nov-2021 RHY - Institutional Investor Presentation
29-Oct-2021 Appendix 4C - quarterly
29-Oct-2021 Appendix 4C - quarterly
26-Oct-2021 Ceasing to be a substantial holder
26-Oct-2021 Ceasing to be a substantial holder
25-Oct-2021 Rhythm Biosciences - Investor Presentation
25-Oct-2021 Rhythm Biosciences - Investor Presentation
22-Oct-2021 Proposed issue of securities - RHY
22-Oct-2021 Proposed issue of securities - RHY
21-Oct-2021 ColoSTAT Test Kits Deliver Consistent, High Accuracy Results
21-Oct-2021 ColoSTAT Test Kits Deliver Consistent, High Accuracy Results
20-Oct-2021 Notice of Annual General Meeting Proxy Form
20-Oct-2021 Notice of Annual General Meeting Proxy Form
5-Oct-2021 Rhythm Receives $2.4m R&D Tax Incentive
5-Oct-2021 Rhythm Receives $2.4m R&D Tax Incentive
4-Oct-2021 Notice Required Under ASX Listing Rule 3.13.1
4-Oct-2021 Notice Required Under ASX Listing Rule 3.13.1
29-Sep-2021 Change in substantial holding
29-Sep-2021 Change in substantial holding
22-Sep-2021 Rhythm Completes Recruitment for Clinical Trial (Study 7)
22-Sep-2021 Rhythm Completes Recruitment for Clinical Trial (Study 7)
14-Sep-2021 TGA Accepts Initial Regulatory Documentation
14-Sep-2021 TGA Accepts Initial Regulatory Documentation
13-Sep-2021 Cleansing Notice
13-Sep-2021 Cleansing Notice
13-Sep-2021 Notification regarding unquoted securities - RHY
13-Sep-2021 Notification regarding unquoted securities - RHY
13-Sep-2021 Application for quotation of securities - RHY
13-Sep-2021 Application for quotation of securities - RHY
9-Sep-2021 Change of Director's Interest Notice x 4
9-Sep-2021 Change of Director's Interest Notice x 4
9-Sep-2021 Notification regarding unquoted securities - RHY
9-Sep-2021 Notification regarding unquoted securities - RHY
9-Sep-2021 Application for quotation of securities - RHY
9-Sep-2021 Application for quotation of securities - RHY
7-Sep-2021 Proposed issue of securities - RHY
7-Sep-2021 Proposed issue of securities - RHY
7-Sep-2021 Rhythm Completes Strongly Oversubscribed $4.3M Rights Issue
7-Sep-2021 Rhythm Completes Strongly Oversubscribed $4.3M Rights Issue
31-Aug-2021 Appendix 4G and Corporate Governance Statement
31-Aug-2021 Appendix 4G and Corporate Governance Statement
31-Aug-2021 Annual Report
31-Aug-2021 Annual Report
31-Aug-2021 Appendix 4E
31-Aug-2021 Appendix 4E
31-Aug-2021 No Extension to Rights Issue Offer Closing Date
31-Aug-2021 No Extension to Rights Issue Offer Closing Date
19-Aug-2021 Initial TGA Regulatory Documentation Submitted
19-Aug-2021 Initial TGA Regulatory Documentation Submitted
10-Aug-2021 Letter to ineligible shareholders
10-Aug-2021 Letter to ineligible shareholders
10-Aug-2021 Non Renounceable pro rata offer - Completion of despatch
10-Aug-2021 Non Renounceable pro rata offer - Completion of despatch
4-Aug-2021 Cleansing Notice
4-Aug-2021 Cleansing Notice
4-Aug-2021 Application for quotation of securities - RHY
4-Aug-2021 Application for quotation of securities - RHY
30-Jul-2021 Securities Trading Policy
30-Jul-2021 Securities Trading Policy
30-Jul-2021 Update - Proposed issue of securities - RHY
30-Jul-2021 Update - Proposed issue of securities - RHY
30-Jul-2021 Rights Issue Investor Presentation
30-Jul-2021 Rights Issue Investor Presentation
30-Jul-2021 Appendix 4C - quarterly
30-Jul-2021 Appendix 4C - quarterly
30-Jul-2021 Proposed issue of securities - RHY
30-Jul-2021 Proposed issue of securities - RHY
30-Jul-2021 Non renouneable rights issue prospectus
30-Jul-2021 Non renouneable rights issue prospectus
30-Jul-2021 Rights issue to raise approximately $4.3 million
30-Jul-2021 Rights issue to raise approximately $4.3 million
28-Jul-2021 Trading Halt
28-Jul-2021 Trading Halt
27-Jul-2021 Proposed issue of securities - RHY
27-Jul-2021 Proposed issue of securities - RHY
26-Jul-2021 Notification regarding unquoted securities - RHY
26-Jul-2021 Notification regarding unquoted securities - RHY
15-Jul-2021 Rhythm Establishes US Entity To Drive US Expansion Strategy
15-Jul-2021 Rhythm Establishes US Entity To Drive US Expansion Strategy
15-Jul-2021 Final Director's Interest Notice
15-Jul-2021 Final Director's Interest Notice
17-Jun-2021 Rhythm to Present at MST Access Investor Conference
17-Jun-2021 Rhythm to Present at MST Access Investor Conference
16-Jun-2021 RHY adds Sonic Clinical Services to ColoSTAT Clinical Trial
16-Jun-2021 RHY adds Sonic Clinical Services to ColoSTAT Clinical Trial
18-May-2021 FY22 Strategic Update
18-May-2021 FY22 Strategic Update
6-May-2021 Rhythm Betters ColoSTAT Results
6-May-2021 Rhythm Betters ColoSTAT Results
27-Apr-2021 Appendix 4C - quarterly
27-Apr-2021 Appendix 4C - quarterly
20-Apr-2021 Appendix 2A and Cleansing Notice
20-Apr-2021 Appendix 2A and Cleansing Notice
13-Apr-2021 Rhythm Extends ColoSTAT Clinical Trial to Western Australia
13-Apr-2021 Rhythm Extends ColoSTAT Clinical Trial to Western Australia
31-Mar-2021 Rhythm Retains ISO13485 Certification
31-Mar-2021 Rhythm Retains ISO13485 Certification
16-Mar-2021 Study 6 Successfully Concluded - Exceptional Results
16-Mar-2021 Study 6 Successfully Concluded - Exceptional Results
25-Feb-2021 Appendix 4D and Half Yearly Report and Accounts
25-Feb-2021 Appendix 4D and Half Yearly Report and Accounts
11-Feb-2021 Rhythm Expands ColoSTAT Clinical Trial To Tenth Site
11-Feb-2021 Rhythm Expands ColoSTAT Clinical Trial To Tenth Site
5-Feb-2021 Appendix 2A and Cleansing Notice
5-Feb-2021 Appendix 2A and Cleansing Notice
29-Jan-2021 Rhythm Top 20 Shareholder Update
29-Jan-2021 Rhythm Top 20 Shareholder Update
28-Jan-2021 Appendix 4C - quarterly
28-Jan-2021 Appendix 4C - quarterly
20-Jan-2021 Initial Manufacturing of ColoSTAT Test-Kits Complete
20-Jan-2021 Initial Manufacturing of ColoSTAT Test-Kits Complete
19-Jan-2021 Rhythm Advances ColoSTAT Study 7
19-Jan-2021 Rhythm Advances ColoSTAT Study 7
11-Jan-2021 Change in substantial holding
11-Jan-2021 Change in substantial holding
ResponsetoASXPriceQuery
ResponsetoASXPriceQuery
2020 Announcements
21-Dec-2020 Investor Presentation - December 2020
21-Dec-2020 Investor Presentation - December 2020
17-Dec-2020 Rhythm Secures US Patent - Strengthens Global Footprint
17-Dec-2020 Rhythm Secures US Patent - Strengthens Global Footprint
2-Dec-2020 Rhythm Appoints Global Manufacturer for ColoSTAT
2-Dec-2020 Rhythm Appoints Global Manufacturer for ColoSTAT
20-Nov-2020 Change of Director's Interest Notice
20-Nov-2020 Change of Director's Interest Notice
19-Nov-2020 Investor Presentation
19-Nov-2020 Investor Presentation
18-Nov-2020 Amended Constitution
18-Nov-2020 Amended Constitution
18-Nov-2020 Results of Meeting
18-Nov-2020 Results of Meeting
18-Nov-2020 AGM Presentation - November 2020
18-Nov-2020 AGM Presentation - November 2020
12-Nov-2020 ColoSTAT Prototype Complete, Outperforms FIT
12-Nov-2020 ColoSTAT Prototype Complete, Outperforms FIT
29-Oct-2020 Appendix 4C - quarterly
29-Oct-2020 Appendix 4C - quarterly
27-Oct-2020 Ethics Approval Received, New Clinical Trial Site Added
27-Oct-2020 Ethics Approval Received, New Clinical Trial Site Added
16-Oct-2020 Rhythm Receives $1.1m R&D Tax Incentive
16-Oct-2020 Rhythm Receives $1.1m R&D Tax Incentive
6-Oct-2020 Notice of Annual General Meeting
6-Oct-2020 Notice of Annual General Meeting
6-Oct-2020 2020 AGM - Letter to Shareholders & Proxy Form
6-Oct-2020 2020 AGM - Letter to Shareholders & Proxy Form
29-Sep-2020 Final Two Adjunct Biomarkers Technically Validated
29-Sep-2020 Final Two Adjunct Biomarkers Technically Validated
23-Sep-2020 New Clinical Trial Site Contracted and Recruiting
23-Sep-2020 New Clinical Trial Site Contracted and Recruiting
16-Sep-2020 Notice Required Under ASX Listing Rule 3.13.1
16-Sep-2020 Notice Required Under ASX Listing Rule 3.13.1
16-Sep-2020 Rhythm Successfully Validates Two Adjunct Biomarkers
16-Sep-2020 Rhythm Successfully Validates Two Adjunct Biomarkers
31-Aug-2020 Appendix 4E
31-Aug-2020 Appendix 4E
28-Aug-2020 Close of Non-Renounceable Rights Issue
28-Aug-2020 Close of Non-Renounceable Rights Issue
25-Aug-2020 Results of Meeting
25-Aug-2020 Results of Meeting
31-Jul-2020 Letter to ineligible shareholders
31-Jul-2020 Letter to ineligible shareholders
31-Jul-2020 Non-renounceable rights issue Offer
31-Jul-2020 Non-renounceable rights issue Offer
31-Jul-2020 Non Renounceable pro rata offer-Completion of despatch
31-Jul-2020 Non Renounceable pro rata offer-Completion of despatch
9-Sep-2020 Cancellation of Options & Current LTI Plan
9-Sep-2020 Cancellation of Options & Current LTI Plan
9-Sep-2020 Notice of change of interests of substantial holder
9-Sep-2020 Notice of change of interests of substantial holder
4-Sep-2020 Notice of Initial Substantial Holder - amended
4-Sep-2020 Notice of Initial Substantial Holder - amended
3-Sep-2020 Notice of initial substantial holder
3-Sep-2020 Notice of initial substantial holder
3-Sep-2020 Change of Director's Interest Notice x 4
3-Sep-2020 Change of Director's Interest Notice x 4
3-Sep-2020 Appendix 2A and Cleansing Notice
3-Sep-2020 Appendix 2A and Cleansing Notice
1-Sep-2020 Entitlement Offer - Results
1-Sep-2020 Entitlement Offer - Results
31-Aug-2020 Appendix 4G and Corporate Governance Statement
31-Aug-2020 Appendix 4G and Corporate Governance Statement
31-Aug-2020 Annual Report
31-Aug-2020 Annual Report
31-Aug-2020 Appendix 4E
31-Aug-2020 Appendix 4E
28-Aug-2020 Close of Non-Renounceable Rights Issue
28-Aug-2020 Close of Non-Renounceable Rights Issue
25-Aug-2020 Results of Meeting
25-Aug-2020 Results of Meeting
31-Jul-2020 Letter to ineligible shareholders
31-Jul-2020 Letter to ineligible shareholders
31-Jul-2020 Non-renounceable rights issue Offer
31-Jul-2020 Non-renounceable rights issue Offer
31-Jul-2020 Non Renounceable pro rata offer-Completion of despatch
31-Jul-2020 Non Renounceable pro rata offer-Completion of despatch
29-Jul-2020 Appendix 2A and Cleansing Notice
29-Jul-2020 Appendix 2A and Cleansing Notice
29-Jul-2020 Appendix 4C - quarterly
29-Jul-2020 Appendix 4C - quarterly
23-Jul-2020 Notice of General Meeting-Proxy Form
23-Jul-2020 Notice of General Meeting-Proxy Form
23-Jul-2020 Cleansing Notice
23-Jul-2020 Cleansing Notice
23-Jul-2020 Proposed issue of Securities - RHY
23-Jul-2020 Proposed issue of Securities - RHY
23-Jul-2020 Placement & Rights Offer to raise approximately $6 million
23-Jul-2020 Placement & Rights Offer to raise approximately $6 million
17-Jul-2020 Trading Halt
17-Jul-2020 Trading Halt
10-Jun-2020 Change of Company Address
10-Jun-2020 Change of Company Address
5-Jun-2020 Appointment of Non-Executive Director & Appendix 3X
5-Jun-2020 Appointment of Non-Executive Director & Appendix 3X
23-Apr-2020 Appendix 4C - quarterly
23-Apr-2020 Appendix 4C - quarterly
9-Apr-2020 COVID-19 Update
9-Apr-2020 COVID-19 Update
6-Apr-2020 Successful ISO13485 Surveillance Audit
6-Apr-2020 Successful ISO13485 Surveillance Audit
2-Apr-2020 Rhythm Successfully Validates Key Biomarker
2-Apr-2020 Rhythm Successfully Validates Key Biomarker
26-Feb-2020 Appendix 4D and Half Yearly Report and Accounts
26-Feb-2020 Appendix 4D and Half Yearly Report and Accounts
30-Jan-2020 Appendix 4C - quarterly
30-Jan-2020 Appendix 4C - quarterly
29-Jan-2020 Change of Auditor
29-Jan-2020 Change of Auditor
6-Jan-2020 Lapse of performance rights - Appendix 3B
6-Jan-2020 Lapse of performance rights - Appendix 3B
2019 Announcements
10-Dec-2019 Appendix 3B - release of escrow securities
10-Dec-2019 Appendix 3B - release of escrow securities
2-Dec-2019 Ceasing to be a substantial holder
2-Dec-2019 Ceasing to be a substantial holder
15-Nov-2019 Release from ASX Escrow
15-Nov-2019 Release from ASX Escrow
4-Nov-2019 Rhythm Biosciences Granted China Patent
4-Nov-2019 Rhythm Biosciences Granted China Patent
29-Oct-2019 Appendix 4C - quarterly
29-Oct-2019 Appendix 4C - quarterly
28-Oct-2019 Appointment of Chairman & Appendix 3X
28-Oct-2019 Appointment of Chairman & Appendix 3X
28-Oct-2019 Results of Meeting
28-Oct-2019 Results of Meeting
28-Oct-2019 AGM Presentation October 2019
28-Oct-2019 AGM Presentation October 2019
25-Oct-2019 Final Director's Interest Notice
25-Oct-2019 Final Director's Interest Notice
25-Oct-2019 Resignation of Director - New Chairman Secured
25-Oct-2019 Resignation of Director - New Chairman Secured
18-Oct-2019 Change in substantial holding
18-Oct-2019 Change in substantial holding
23-Sep-2019 Change in substantial holding
23-Sep-2019 Change in substantial holding
19-Sep-2019 ColoSTAT - Test Development Update
19-Sep-2019 ColoSTAT - Test Development Update
17-Sep-2019 Notice of Annual General Meeting-Proxy Form
17-Sep-2019 Notice of Annual General Meeting-Proxy Form
29-Aug-2019 Appendix 4G and Corporate Governance Statement
29-Aug-2019 Appendix 4G and Corporate Governance Statement
29-Aug-2019 Annual Report
29-Aug-2019 Annual Report
29-Aug-2019 Appendix 4E
29-Aug-2019 Appendix 4E
25-Jul-2019 Corporate Presentation - July 2019
25-Jul-2019 Corporate Presentation - July 2019
25-Jul-2019 Appendix 4C
25-Jul-2019 Appendix 4C
26-Jun-2019 Rhythm signs Alfred Hospital for ColoSTAT clinical trial
26-Jun-2019 Rhythm signs Alfred Hospital for ColoSTAT clinical trial
18-Jun-2019 Monash Health signed with first patients recruited
18-Jun-2019 Monash Health signed with first patients recruited
22-May-2019 Rhythm Biosciences receives ISO certification
22-May-2019 Rhythm Biosciences receives ISO certification
30-Apr-2019 Appendix 4C - quarterly
30-Apr-2019 Appendix 4C - quarterly
18-Mar-2019 Rhythm recruits first patient in ColoSTAT clinical trial
18-Mar-2019 Rhythm recruits first patient in ColoSTAT clinical trial
26-Feb-2019 Appendix 4D and Half Yearly Report and Accounts
26-Feb-2019 Appendix 4D and Half Yearly Report and Accounts
20-Feb-2019 RHY Signs first ColoSTAT site for Clinical Trial - Study 7
20-Feb-2019 RHY Signs first ColoSTAT site for Clinical Trial - Study 7
11-Feb-2019 Corporate Presentation
11-Feb-2019 Corporate Presentation
8-Feb-2019 Rhythm secures ethics approval for ColoSTAT clinical trial
8-Feb-2019 Rhythm secures ethics approval for ColoSTAT clinical trial
29-Jan-2019 Appendix 4C
29-Jan-2019 Appendix 4C
23-Jan-2019 RHY Welcomes Australian Government's $10m Investment
23-Jan-2019 RHY Welcomes Australian Government's $10m Investment
2018 Announcements
11-Dec-2018 Rhythm Receives R&D Tax Incentive Refund
11-Dec-2018 Rhythm Receives R&D Tax Incentive Refund
5-Dec-2018 Rhythm Completes Reagent Development Program
5-Dec-2018 Rhythm Completes Reagent Development Program
28-Nov-2018 Appointment of CEO - Senior Management Changes
28-Nov-2018 Appointment of CEO - Senior Management Changes
26-Nov-2018 Results of Meeting
26-Nov-2018 Results of Meeting
26-Nov-2018 AGM Presentation
26-Nov-2018 AGM Presentation
14-Nov-2018 Change of Director's Interest Notice
14-Nov-2018 Change of Director's Interest Notice
29-Oct-2018 Appendix 4C
29-Oct-2018 Appendix 4C
12-Oct-2018 Notice of Annual General Meeting-Proxy Form
12-Oct-2018 Notice of Annual General Meeting-Proxy Form
3-Oct-2018 Final Antibody Selection Complete
3-Oct-2018 Final Antibody Selection Complete
31-Aug-2018 Appendix 4G and Corporate Governance Statement
31-Aug-2018 Appendix 4G and Corporate Governance Statement
31-Aug-2018 Annual Report
31-Aug-2018 Annual Report
31-Aug-2018 Appendix 4E
31-Aug-2018 Appendix 4E
29-Aug-2018 Appendix 3B - release from escrow
29-Aug-2018 Appendix 3B - release from escrow
13-Aug-2018 Change in substantial holding
13-Aug-2018 Change in substantial holding
6-Aug-2018 Release of Restricted Securities from Escrow
6-Aug-2018 Release of Restricted Securities from Escrow
30-Jul-2018 Appendix 4C
30-Jul-2018 Appendix 4C
21-Jun-2018 Rhythm completes cloning of key reagent ahead of schedule
21-Jun-2018 Rhythm completes cloning of key reagent ahead of schedule
15-Jun-2018 Merchant Group increases stake in Rhythm from 5% to 7%
15-Jun-2018 Merchant Group increases stake in Rhythm from 5% to 7%
12-Jun-2018 RHY Welcomes Leading Biotech Fund as New Major Shareholder
12-Jun-2018 RHY Welcomes Leading Biotech Fund as New Major Shareholder
22-May-2018 Appendix 3B
22-May-2018 Appendix 3B
22-May-2018 Key Management Appointments at Rhythm Biosciences
22-May-2018 Key Management Appointments at Rhythm Biosciences
16-May-2018 Rhythm Granted Biomarker Patent in Europe
16-May-2018 Rhythm Granted Biomarker Patent in Europe
14-May-2018 RHY's Four Antibodies Pass all Three Key Screening Tests
14-May-2018 RHY's Four Antibodies Pass all Three Key Screening Tests
30-Apr-2018 Appendix 4C
30-Apr-2018 Appendix 4C
24-Apr-2018 Reagent Development Update
24-Apr-2018 Reagent Development Update
23-Mar-2018 Change of Director's Interest Notice
23-Mar-2018 Change of Director's Interest Notice
1-Mar-2018 Appendix 4D - Half Yearly Report
1-Mar-2018 Appendix 4D - Half Yearly Report
27-Feb-2018 Half Yearly Report and Accounts
27-Feb-2018 Half Yearly Report and Accounts
15-Feb-2018 Consultation with Major Diagnostic Labs Underway - Update
15-Feb-2018 Consultation with Major Diagnostic Labs Underway - Update
7-Feb-2018 Rhythm reports reagent development update
7-Feb-2018 Rhythm reports reagent development update
31-Jan-2018 Quarterly report and Appendix 4C
31-Jan-2018 Quarterly report and Appendix 4C
24-Jan-2018 CSIRO and Rhythm Commence Development of Key Reagents
24-Jan-2018 CSIRO and Rhythm Commence Development of Key Reagents
9-Jan-2018 CSIRO to assist Rhythm Biosciences develop key reagents
9-Jan-2018 CSIRO to assist Rhythm Biosciences develop key reagents
2017 Announcements
7-Dec-2017 Becoming a substantial holder
7-Dec-2017 Becoming a substantial holder
6-Dec-2017 Appendix 3X - Lockett
6-Dec-2017 Appendix 3X - Lockett
6-Dec-2017 Appendix 3X - Tanner
6-Dec-2017 Appendix 3X - Tanner
6-Dec-2017 Appendix 3X - Panaccio
6-Dec-2017 Appendix 3X - Panaccio
6-Dec-2017 Appendix 3X - White
6-Dec-2017 Appendix 3X - White
6-Dec-2017 Corporate Governance Statement
6-Dec-2017 Corporate Governance Statement
6-Dec-2017 Audited Special Purpose Report 1-6-17 to 30-6-17
6-Dec-2017 Audited Special Purpose Report 1-6-17 to 30-6-17
6-Dec-2017 Audited Special Purpose Report 1-7-17 to 31-8-17
6-Dec-2017 Audited Special Purpose Report 1-7-17 to 31-8-17
6-Dec-2017 Securities Trading Policy
6-Dec-2017 Securities Trading Policy
6-Dec-2017 Performance Rights Plan
6-Dec-2017 Performance Rights Plan
6-Dec-2017 Employee Security Ownership Plan
6-Dec-2017 Employee Security Ownership Plan
6-Dec-2017 Constitution
6-Dec-2017 Constitution
6-Dec-2017 Top 20 Shareholders
6-Dec-2017 Top 20 Shareholders
6-Dec-2017 Distribution Schedule
6-Dec-2017 Distribution Schedule
6-Dec-2017 Pre-quotation Disclosure
6-Dec-2017 Pre-quotation Disclosure
6-Dec-2017 Appendix 1A and Information Form and Checklist
6-Dec-2017 Appendix 1A and Information Form and Checklist
6-Dec-2017 Replacement Prospectus
6-Dec-2017 Replacement Prospectus
6-Dec-2017 Admission to Official List
6-Dec-2017 Admission to Official List
6-Dec-2017 ASX Notice - Admission and Quotation
6-Dec-2017 ASX Notice - Admission and Quotation

Annual Financial Report

Annual Financial Report - 2025
Annual Financial Report - 2025
Annual Financial Report - 2024
Annual Financial Report - 2024
Annual Financial Report - 2023
Annual Financial Report - 2023
Annual Financial Report - 2022
Annual Financial Report - 2022
Annual Financial Report - 2021
Annual Financial Report - 2021
Annual Financial Report - 2020
Annual Financial Report - 2020
Annual Financial Report - 2019
Annual Financial Report - 2019
Annual Financial Report - 2018
Annual Financial Report - 2018
Half Yearly Financial Report - 31 December 2018
Half Yearly Financial Report - 31 December 2018
Rhythm Biosciences Financial Report 30 June 2017
Rhythm Biosciences Financial Report 30 June 2017
Special Purpose Financial Report - 31 August 2017
Special Purpose Financial Report - 31 August 2017
Half Yearly Financial report - 31 December 2017
Half Yearly Financial report - 31 December 2017

Corporate Governance

Continuous Disclosure Policy
Continuous Disclosure Policy
Corporate Governance Pack
Corporate Governance Pack
Whistleblower Policy
Whistleblower Policy
Rhythm Speak Up Form
Rhythm Speak Up Form
Securities Trading Policy
Securities Trading Policy
Rhythm Biosciences Constitution
Rhythm Biosciences Constitution

Analyst Reports

17 February 2026 - ColoSTAT Comeback, with Genetype upside
17 February 2026 - ColoSTAT Comeback, with Genetype upside
27 October 2023 - MST Access 'Screening Markets Expanding'
27 October 2023 - MST Access 'Screening Markets Expanding'
29 November 2022 - MST Access "Update"
29 November 2022 - MST Access "Update"
5 July 2022 - MST Access "Approval to Unblock an Expanded Market"
5 July 2022 - MST Access "Approval to Unblock an Expanded Market"
21 April 2022 - MST Access " Update - Study 7 Opens Market Opportunities"
21 April 2022 - MST Access " Update - Study 7 Opens Market Opportunities"
12 April 2022 - Pitt Street Reserach "Update - Study 7 is Another Success"
12 April 2022 - Pitt Street Reserach "Update - Study 7 is Another Success"
7 December 2021 - Pitt Street Research "Ticket booked to Europe"
7 December 2021 - Pitt Street Research "Ticket booked to Europe"
12 November 2021 - MST Access " Market Entries in Sight"
12 November 2021 - MST Access " Market Entries in Sight"
17 June 2021 - MST Access "Breakthrough Bowel Cancer Diagnostic"
17 June 2021 - MST Access "Breakthrough Bowel Cancer Diagnostic"
18 May 2021 - Pitt Street Research " Bowel Cancer Screening Made Simple"
18 May 2021 - Pitt Street Research " Bowel Cancer Screening Made Simple"
RHYTHM BIOSCIENCES

Contact

Rhythm Biosciences

Bio21 Institute
30 Flemington Road
Parkville VIC 3010
Australia

Keep up to date:

Connect with us:

JOIN OUR
MAILING LIST